Barclays PLC Bolt Biotherapeutics, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 139 shares of BOLT stock, worth $105. This represents 0.0% of its overall portfolio holdings.
Number of Shares
139
Previous 139
-0.0%
Holding current value
$105
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding BOLT
# of Institutions
40Shares Held
24.3MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA3.52MShares$2.68 Million0.66% of portfolio
-
Tang Capital Management LLC San Diego, CA3.42MShares$2.6 Million0.58% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.75MShares$2.09 Million0.22% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.42MShares$1.84 Million0.0% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA1.89MShares$1.44 Million1.94% of portfolio
About Bolt Biotherapeutics, Inc.
- Ticker BOLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,641,500
- Market Cap $28.6M
- Description
- Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...